RxDoctor Payments Data

Martin Pollak, MD

Nephrology · Boston, MANPI 1720096738

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $19,750,000 of the $19,770,862 with a category attached, or 99.9%. Vertex accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2021 at $18,751,435 and has fallen 100.0% since, to $28 in 2025. Among nephrology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,770,862in general payments, 2019–2025

Across 23 payments — averaging $859,603 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$19.8M
  • Travere Therapeutics, Inc.$39
$4,673,381in research payments, 2019–2025

Across 6 payments — averaging $778,897 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$4.7M

What the payments were for

  • Royalty or licence$19,750,000100%
  • Consulting fees$14,5550%
  • Speaking & faculty fees$6,0210%
  • Food & beverage$2840%
  • Education$30%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vertex21$19,770,823
Travere Therapeutics, Inc.2$39

How this compares

$19,770,862 in reported general payments places this provider in the 95th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$7,673
Medicare patients
42
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →